Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Cash from Investing Activities (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of Cash from Investing Activities readings, the most recent being -$52.9 million for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities rose 22.55% to -$52.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$264.4 million, a 108.52% decrease, with the full-year FY2025 number at -$264.4 million, down 108.52% from a year prior.
  • Cash from Investing Activities hit -$52.9 million in Q4 2025 for Neurocrine Biosciences, up from -$196.7 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $63.1 million in Q1 2021 to a low of -$201.8 million in Q4 2023.
  • Median Cash from Investing Activities over the past 5 years was -$54.0 million (2024), compared with a mean of -$58.3 million.
  • Biggest five-year swings in Cash from Investing Activities: soared 134.58% in 2022 and later crashed 896.36% in 2025.
  • Neurocrine Biosciences' Cash from Investing Activities stood at $23.7 million in 2021, then tumbled by 587.76% to -$115.6 million in 2022, then tumbled by 74.57% to -$201.8 million in 2023, then skyrocketed by 66.15% to -$68.3 million in 2024, then grew by 22.55% to -$52.9 million in 2025.
  • The last three reported values for Cash from Investing Activities were -$52.9 million (Q4 2025), -$196.7 million (Q3 2025), and -$29.0 million (Q2 2025) per Business Quant data.